Tuesday, Candel Therapeutics, Inc. (CADL) announced that the FDA has granted Fast Track Designation to Can-3110.
Can-3110 is a first-in-class oncolytic viral immunotherapy candidate for treating patients with recurrent high-grade glioma to enhance overall survival.
The President and CEO of Candel, Paul Peter Tak, stated that further data, including the benefits of multiple injections, will be reported from the phase 1b clinical trial in the second half of 2024.
The company also said that it expects to initiate the IND process in a second indication characterized by Nestin expression.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.